Ivan Hyep Sells 9,200 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $20.42, for a total value of $187,864.00. Following the sale, the chief financial officer owned 145,355 shares in the company, valued at $2,968,149.10. This trade represents a 5.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ivan Hyep also recently made the following trade(s):

• On Tuesday, April 21st, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The stock was sold at an average price of $23.00, for a total value of $211,600.00.
• On Monday, March 23rd, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.52, for a total value of $170,384.00.
• On Wednesday, March 4th, Ivan Hyep sold 2,963 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.25, for a total value of $54,074.75.
• On Tuesday, March 3rd, Ivan Hyep sold 13,555 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.22, for a total value of $246,972.10.

Bicara Therapeutics Stock Performance

BCAX opened at $21.58 on Thursday. The business’s 50-day simple moving average is $21.27 and its 200-day simple moving average is $18.49. Bicara Therapeutics Inc. has a one year low of $8.48 and a one year high of $24.25. The stock has a market capitalization of $1.42 billion, a P/E ratio of -7.76 and a beta of -0.57.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). On average, equities research analysts forecast that Bicara Therapeutics Inc. will post -3.37 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Morgan Stanley raised their price target on Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. The Goldman Sachs Group raised their price target on Bicara Therapeutics from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Tuesday, May 12th. Wells Fargo & Company raised their price target on Bicara Therapeutics from $11.00 to $16.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of Bicara Therapeutics in a report on Wednesday. Finally, Guggenheim assumed coverage on Bicara Therapeutics in a report on Monday, May 11th. They set a “buy” rating and a $42.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $30.27.

Institutional Investors Weigh In On Bicara Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Bicara Therapeutics in the fourth quarter valued at about $45,000. Legal & General Group Plc lifted its position in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares during the period. Larson Financial Group LLC lifted its position in Bicara Therapeutics by 1,015.5% in the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after purchasing an additional 3,595 shares during the period. Tower Research Capital LLC TRC lifted its position in Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after purchasing an additional 3,866 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its position in Bicara Therapeutics by 385.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after purchasing an additional 4,585 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.